IMR Press / FBL / Volume 5 / Issue 4 / DOI: 10.2741/hargreav

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones
Show Less
1 CRC Drug Development Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, U.K.
2 CRC Drug-DNA Interactions Research Group, Department of Oncology, Royal Free and University College Medical School, UCL, 91 Riding House Street, London W1P 8BT, U.K.
3 Department of Biological Sciences, Salford University, Salford M5 4WT, United Kingdom
Academic Editor:Peter Gutierrez
Front. Biosci. (Landmark Ed) 2000, 5(4), 172–180; https://doi.org/10.2741/hargreav
Published: 1 November 2000
(This article belongs to the Special Issue Mechanisms of action of quinone-containing alkylating agents)
Abstract

Aziridinyl quinones can be activated by cellular reductases eg. DT-diaphorase and cytochrome P450 reductase to form highly reactive DNA alkylating agents. The mechanisms by which this activation and alkylation take place are many and varied. Using clinically relevant and experimental agents this review will describe many of these mechanisms. The agents discussed are Mitomycin C, EO9 and analogues, diaziridinylbenzoquinones and the pyrrolo[1, 2-alpha]benzimidazolequinones.

Keywords
DNA alkylation
Quinone Anti-Cancer Agents
Review
Share
Back to top